RECRUITINGINTERVENTIONAL

EEG Microstates Across At-Risk Mental States

Determination of EEG Microstates Associated With Mental Disorders in At-Risk States (Détermination Des Microétats EEG associés Aux Troubles Psychiques Dans Les États à Risque - DEMETER)

About This Trial

The goal of this observational study is to compare subjects with at-risk-mental-state, early psychosis, schizophrenia, depression, and autism spectrum disorders, with healthy controls (N = 21 x 6). The main questions it aims to answer are: * are EEG microstate anomalies associated with diagnosis, clinical and functional prognosis, both in resting conditions and during sleep ? * are EEG microstates anomalies associated with differences in sensorimotor integration, prosodic and conversational, interoceptive, and narrative self ? * an ancillary study will be to see whether in healthy controls EEG microstate properties vary under light hypnosis conditions. Participants will: * undergo deep phenotyping based on psychopathology and neuropsychological assessments * undergo a high-resolution EEG (64 electrodes) with a resting period and a sensorimotor task; and healthy controls will have a light hypnosis period. * undergo a recording of the characteristics of their voice (tone, prosody) * undergo a one-night polysomnography * undergo MRI and biological sampling for multi-omic analyses * undergo a virtual reality experience

Who May Be Eligible (Plain English)

Who May Qualify: - age between 15 and 30 years - subjects meeting CAARMS criteria for stage Ia or Ib mental states at risk (for stage Ia, mild or nonspecific symptoms of psychosis or severe mood disorder, and mild functional impairment; for stage Ib, moderate symptoms below intervention threshold and moderate functional impairment) - subjects meeting any DSM-5 criteria associated with a first onset of psychotic symptoms (first episode psychosis) - subjects satisfying DSM-5 criteria for depressive disorder - subjects meeting DSM-5 criteria for autism spectrum disorder - healthy control subjects recruited from the general population Who Should NOT Join This Trial: - suicidal risk - severe or non-stabilized somatic and neurological disorders - epilepsy - head trauma - IQ below 70 - for healthy control subjects, a family history of psychosis is an exclusion criterion - bipolar disorder - obsessive-compulsive disorder - substance use disorder, except for cannabis, tolerated up to 5 joints/day. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * age between 15 and 30 years * subjects meeting CAARMS criteria for stage Ia or Ib mental states at risk (for stage Ia, mild or nonspecific symptoms of psychosis or severe mood disorder, and mild functional impairment; for stage Ib, moderate symptoms below intervention threshold and moderate functional impairment) * subjects meeting any DSM-5 criteria associated with a first onset of psychotic symptoms (first episode psychosis) * subjects satisfying DSM-5 criteria for depressive disorder * subjects meeting DSM-5 criteria for autism spectrum disorder * healthy control subjects recruited from the general population Exclusion Criteria: * suicidal risk * severe or non-stabilized somatic and neurological disorders * epilepsy * head trauma * IQ below 70 * for healthy control subjects, a family history of psychosis is an exclusion criterion * bipolar disorder * obsessive-compulsive disorder * substance use disorder, except for cannabis, tolerated up to 5 joints/day.

Treatments Being Tested

DEVICE

EEG 64 channels

64-channel EEG in wake and resting conditions for 1h30, with oculogram, electromyogram and electromyogram and electrocardiogram. Five minutes of eyes closed will be used for microstate analysis. 1h30 will be used for the sensorimotor task.

DEVICE

Polysomnography 19 electrodes

Overnight polysomnography with 19 EEG channels and ventilatory polygraphy.

BEHAVIORAL

Light hypnosis

Healthy controls will undergo a 5 min light hypnosis exercise that will be focused on proprioception.

BIOLOGICAL

Biological sampling

Blood samples will be taken for genetic, epigenetic, proteomic, and metabolomic studies.

BEHAVIORAL

Virtual reality

Participants will undergo a virtual reality task using a head-mounted display, and their multidimensional self will be assessed prior to and after the task via the self-reference effect on episodic memory.

DEVICE

Voice recording

A double channel audio recorder will be used during 30 min to assess voice characteristics of all subjects.

Locations (1)

Centre de Recherche Clinique, Hôpital Sainte-Anne, GHU Paris Psychiatrie et Neurosciences

Paris, France